Open access

Gene Modulation by Peptide Nucleic Acids (PNAs) Targeting microRNAs (miRs)

Written By

Rosangela Marchelli, Roberto Corradini, Alex Manicardi, Stefano Sforza, Tullia Tedeschi, Enrica Fabbri, Monica Borgatti, Nicoletta Bianchi and Roberto Gambari

Submitted: November 11th, 2010 Published: August 23rd, 2011

DOI: 10.5772/21081

Chapter metrics overview

2,787 Chapter Downloads

View Full Metrics

1. Introduction

Since non-viral gene therapy was developed and employed in different in vitroand in vivoexperimental systems as an effective way to control and modify gene expression, RNA has been considered as a molecular target of great relevance (Li &Huang, 2008, López-Fraga et al., 2008). In combination with standard chemotherapy, the siRNA therapy can reduce the chemoresistance of certain cancers, demonstrating its potential for treating many malignant diseases. Examples of RNA sequences to be targeted for therapeutic applications are mRNAs coding oncoproteins or RNA coding anti-apoptotic proteins for the development of anti-cancer therapy.

In the last years, progresses in molecular biology have allowed to identify many genes Coding for small non coding RNA molecules, microRNA (miRNAs or miRs), able to regulate gene expression at the translation level (Huang et al., 2008, Shrivastava & Shrivastava, 2008, Sahu et al. 2007, Orlacchio et al., 2007, Williams et al., 2008, Papagiannakopoulos & Kosik, 2008). Accordingly, an increasing number of reports associate the changed expression with specific phenotypes and even with pathological conditions (Garzon & Croce, 2008, Mascellani et al., 2008, Sontheimer & Carthew, 2005, Filipowicz et al., 2005, Alvarez-Garcia & Miska, 2005). Interestingly, microRNAs play a double role in cancer, behaving both as oncogenes or tumor suppressor genes. In general, miRs promoting cancer targets mRNA coding for tumor-suppression proteins, while microRNAs exhibiting tumor-suppression properties usually target mRNAs coding oncoproteins. MicroRNAs which have been demonstrated to play a crucial role in the initiation and progression of human cancer are defined as oncogenic miRNAs (oncomiRs) (Cho, 2007). The oncomiR expression profiling of human malignancies has also identified a number of diagnostic and prognostic cancer signals (Cho, 2007, Lowery et al., 2008). Moreover, microRNAs have been firmly demonstrated to be involved in cancer metastasis (metastamiRs).

Examples of metastasis-promoting microRNAs are, miR-10b (Calin et al., 2006), miR-373 and -520c (Woods et al., 2007), miR-21, -143 and -182 (Hayashita et al., 2005; Si et al., 2007; Zhu et al., 2007). Reviews on metastamiR has been recently published Hurst et al. (Hurst et al. 2009, Edmonds et al. 2009). Reviews on metastamiRs has been recently published by Hurst et al. Table 1 shows examples of microRNAs involved in cancer onset and progression.

MicroRNAsTumorTarget mRNAReference(s)
miR-17-92Lung cancer, lymphomaE2F1Woods et al., 2007
miR-21Breast cancer, cholangiocarcinoma, head & neck cancer, leukemia, cervical cancertropomyosin 1
Iorio et al., 2005;
Zhu et al., 2007
miR-155Breast cancer, leukemia, pancreatic cancer, B-cell lymphomaFOXO3a; SHIP1
Costinean et al., 2006;
Kong et al.,
Pedersen et al., 2009
miR-221GlioblastomaPUMACiafre et al., 2005;
Zhang et al., 2010
miR-222Thyroid carcinomaP27Kip1Visone et al., 2007
miR-31Lung cancerLATS2Liu et al., 2010

Table 1.

Examples of microRNAs involved in cancer onset and their putative targets.

Thus, therapeutic strategies involving miRNA silencing could be proposed based on the roles of these small non-coding RNAs as oncogenes. For these reasons, the development of molecules able to specifically recognize microRNA target sequences is of particular interest, from both a diagnostic and a therapeutic point of view.

Indeed, miRNAs can be antagonized in vivoby highly-affine oligonucleotides (Lowery et al., 2008, Stenvang & Kauppinen, 2008). Up to now synthetic oligonucleotides have been used for targeting microRNAs, although with several problems, including delivery and stability. However, the use of oligonucleotide analogues has recently been proposed to be effective for the inhibition of miR expression and, accordingly, as a potent tool for the regulation of gene expression (Kota & Balasubramanian, 2010).

Peptide nucleic acids (PNAs) (figure 1) are DNA analogues in which the sugar-phosphate backbone is replaced by N-(2-aminoethyl)glycine units (Nielsen et al., 1991, Nielsen and Egholm, 1999, Lundin et al., 2006).

Figure 1.

Structure of DNA and PNA

These molecules efficiently hybridize with complementary DNA and RNA, forming Watson-Crick double helices. In addition, they can generate triple helix structures with double stranded DNA and perform strand invasion. Accordingly, they have been proposed for antisense and anti-gene therapy in a great number of studies (Larsen and Nielsen, 1996, Gambari, 2004, Nielsen 2005, 2006, Yin et al. 2008). PNAs are very promising for RNA recognition, since they have a higher affinity for RNA than for DNA, are more specific and are resistant to DNAses and proteases (Demidov et al 1994).

PNAs can be modified in order to achieve better performances in terms of cellular permeation, higher affinity, and specificity for the target DNA and RNA sequences (Corradini et al., 2004, 2007, Sforza et al., 2000, 2007, 2010, Tedeschi et al., 2005 a,b,c, Wojciechowski and Hudson, 2007, Dragulescu-Andrasi 2005, Rapireddy 2007).

In this chapter we will describe the recent results reported in the literature by using PNAs as anti-miR agents and the perspectives of this technology for future development.


2. MiR targeting: therapeutic significance

MicroRNAs are a family of small (19 to 25 nucleotide in length) noncoding RNAs that regulate gene expression by sequence-selective targeting of mRNAs, leading to a translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and the target sequences (Krol et al., 2010).

The expression pathway of these molecules consists in several steps as depicted in figure 2.

Figure 2.

Pathways of miR production and action. The primary transcript microRNA (pri-miR) is processed by DROSHA in combination with other factors such as DGCR8 to yield an hairpin structure called pre-miR, which is then exported by exportin 5 to the cytoplasm where it is cleaved by DICER in combination with other factors. The mature 21-23nt long dsRNA is processed by incorporation of the guiding strand into the miRISC complex, which act as inhibitor of translation, by either degradation of the mRNA bearing the target sequence or by incorporation of the miRISC-mRNA complex into the P-body, leading to inactivation.

Since their discovery and first characterization, the number of microRNA sequences deposited in the miRBase databases is significantly growing (Kozomara & Griffiths-Jones, 2010). On the other hand, considering that a single miRNA can target several mRNAs and a single mRNA might contain in the 3’UTR sequence several signals for miRNA recognition, it can be calculated that at least 10-40% of human mRNAs are targets for microRNAs (He & Hannon, 2004). Therefore, a great interest is concentrated on the identification of validated targets of microRNAs. This specific field of research has confirmed that the complex networks constituted by miRNAs and RNA targets coding for structural and regulatory proteins leads to the control of highly regulated biological functions, such as differentiation (Masaki et al., 2007), cell cycle (Wang & Blelloch, 2009) and apoptosis (Subramanian & Steer, 2010).

More in detail, and considering the role of microRNAs, a low expression of a given miR is expected to be linked with a potential accumulation of targets mRNAs; conversely, a high expression of miRNAs is expected to be responsible for a low expression of the target mRNAs.

However, since a single 3’UTR of a given mRNA contains signal sequences for several microRNAs, which microRNA should be targeted in order to achieve alteration of the expression of the gene should be experimentally evaluated. With respect to the possible effects of the expression of other mRNA targets, it should be clearly stated that alteration of a single microRNA might retain multiple effects. Finally, multiple targeting of several microRNAs might be considered for achieving strong biological effects. Whatever strategy is considered, several examples of biological effects of targeting microRNA involved in human pathologies are already available in the literature.


3. MiR targets relevant in gene therapy

The number of known microRNAs which regulate gene expression is continuously growing, with 1048 sequences present to date in the miRbase for humans (as available on march 30th, 2011 at

Although the discovery of new miRNA is presently carried out using massive sequencing technologies (Kozomara & Griffiths-Jones, 2010), the miR targets important in biochemical processes rely on comparison schemes. As a general rule, selection of the target miRNA can be achieved using the microarray approach by quantitative analyisis of the miR profile in a particular cellular state compared to a control lineage. MiR specific RT-PCR protocols can be used, followed by hybridization to specialized miR microarrays. This analysis has been used to identify miR targets which are over- or, more frequently, under-expressed under pathological conditions. Moreover, several very important miR targets have been addressed by many studies on account of the fact that they were able to act as critical points in the regulation of pathological states.

Chemically engineered oligonucleotides, termed 'antagomirs', are efficient and specific silencers of endogenous miRNAs in mice. Silencing of microRNAs in vivo with 'antagomirs' is a very interesting strategy, supporting studies on the involvement of miRs in gene expression and providing new tools for non-viral gene therapy (Czech, 2006).

MiR-155 is one of the first known miR to be overexpressed in cancers, especially in those occurring in B-cells; high level of this miR have been associated to several neoplastic states and to autoimmune diseases, since it leads to the suppression of a large number of genes involved in the control of cellular proliferation. Therefore miR-155 has been identified as possible target for gene therapy associated to lymphomas and chronic lymphocytic leukemias and colorectal cancer (Zhang et al., 2007, Kota & Balasubrasmanian, 2010). Furthermore, miR-155 was shown to control inflammatory response to microbes (Ceppia et al., 2009).

MiR-21 overexpression was shown to be associated to several solid tumours (lung, breast, colon, gastric and prostate carcinomas and endocrine pancreatic tumours) as well as to cholangiocarcinoma and glioblastoma, since it is correlated to inhibition of apoptosis (Calin & Croce, 2006, Papagiannakopoulos et al., 2008). Knock down of this miR by locked nucleic acids (LNA) oligonucleotides, associated with neural precursor cells (NPC) expressing a secretable variant of the cytotoxic agent tumor necrosis factor–related apoptosis inducing ligand (S-TRAIL), was shown to have high antitumor activity (Corsten et al., 2007).

MiR-122 is another very important target: it is a well characterized liver-specific microRNA exhibiting particular therapeutic interest, since it is related to cholesterol levels in plasma, and it has been shown not only to facilitate Hepatitis C RNA replication (Jopling et al., 2005) but also to be up-regulated in HIV-1 infected cells (Triboulet et al., 2007). Krützfeldt and coworkers (Krützfeldt et al., 2005) demonstrated that intravenous administration of antagomirs against several miRs, including miR-122, resulted in a marked reduction of the corresponding miRNA levels in liver, lung, kidney, heart, intestine, fat, skin, bone marrow, muscle, ovaries and adrenals. The silencing of endogenous miRNAs by this novel method is specific, efficient and long-lasting. The biological significance of silencing miRNAs with the use of antagomirs was studied with miR-122. Gene expression and bioinformatic analysis of messenger RNA from antagomir-treated animals revealed that the 3' untranslated regions of upregulated genes are strongly enriched in miR-122 recognition motifs, whereas down-regulated genes are depleted of these motifs. These findings show that antagomirs are powerful tools to silence specific miRNAs in vivo and may represent a therapeutic strategy for silencing miRNAs in disease. This was confirmed by Elmén et al. (Elmén et al., 2008a), who demonstrated that antagonism of microRNA-122 in mice, systemically treated with LNA-antimiR, leads to up-regulation of a large set of predicted target mRNAs in the liver. These results were also confirmed in non-human primates (Elmén et al.,2008b), showing that lowering of plasma cholesterol could be achieved without signs of toxicity.

That interest on this target has been recently boosted by a report which showed increased resistance to chronic hepatitis C virus (HCV) in primates was achieved by targeting miR122 with LNA, with long-lasting suppression of HCV viremia, with no evidence of viral resistance or side effects in the treated animals (Landfrod et al., 2010).

MiR-221 and mir-222 have been shown to be associated to the suppression of p27Kip1, a cell cycle inhibitor and tumor suppressor; high levels of these miRs are present in glioblastoma (Le Sage et al 2007) and have been proposed as very important therapeutic targets.

More recently, miR-210 was identified as an highly expressed miR in the erythroid precursor cells from a patient exhibiting hereditary persistence of fetal haemoglobin (HPFH). When RT-PCR was performed on mithramycin-induced K562 cells and erythroid precursor cells, miR-210 was found to be induced in time-dependent and dose-dependent fashion, together with increased expression of the fetal γ-globin genes (Bianchi et al., 2009). Thus miR-210 plays a crucial role in the erythroid differentiation pathway, by limiting the expression of genes whose down-modulation might be associated with the progression of erythroid differentiation.

Other highly expressed miRs (such as miR-142-3p) are very important tools in gene therapy protocols since specific targets can be inserted in gene constructs in order to suppress toxicity associated to viral vectors or to inhibit immune response against a transgene, but they are not easily used as targets for specific inhibition of a pathological state (Brown & Naldini, 2009).


4. MiR targeting by PNAs

PNAs are very promising tools for RNA recognition, since they have a higher affinity for RNA than for DNA (Nielsen, 2004), are more specific and are resistant to DNases and proteases (Demidov et al 1994).

As far as their role in targeting mRNAs in the antisense strategy, it should be underlined that, unlike oligonucleotide (ON) molecules, PNAs do not activate the RNAse H mediated degradation (Bonham et al., 2005). However, since the RNAse H degradation was shown not to be effective in the inhibition of miR by oligonucleotides, the steric block mechanism, i.e. the base pairing of the therapeutic ON with one of the strands of the miR target, should be one of the possible mechanisms, although a degradation of the miR target by a still unknown mechanism has been proposed for some ON derivatives (Krutzfeldt et al., 2007).

The steric block mechanism is highly efficient when using PNAs, due to their high affinity for RNA, and the high stability to both chemical and enzymatic degradation (Demidov et al., 1994).

However, very few works have been reported so far concerning the use of PNAs as anti-miR agents, showing good performances (table 2). One of the reasons is the lack of cellular permeation by simple unmodified PNA, or segregation in lysosomes of some PNA-peptide conjugates, which can prevent the access to the target miRNA. However, these problems can be easily circumvented by using appropriate carriers, as shown by our own experience and by other examples reported in the next paragraph.

Ref.targetsPNA modificationCellular /animal systemEffect
Fabani et al., 2008miR-122K-PNA-K3human hepatocellular
carcinoma cells
primary rat hepatocytes
Decrease in miR-122 and mRNA of its target genes (Aldolase A)
Oh et al ., 2009miR-16
Different cell penetrating peptides (CPP)
Most effective:
HeLa cellsUpregulation of mRNA targets measured by luciferase assay
Fabani et al., 2010miR-155K-PNA-K3LPS-activated primary B cells
and mice
Up-regulation of 724 transcripts
Fabbri et al., 2011miR-210R8-PNAK562 chronic myelogenous leukemia cellsAlteration of erythroid differentiation

Table 2.

Works reporting PNA induced miR suppression.

able 2.

The first example of targeting microRNAs using PNA-based molecules is provided by miR-122. Fabani and Gait demonstrated, using PNAs and PNA-peptide conjugates, that these oligonucleotide analogs, evaluated for the first time in microRNA inhibition, are more effective than standard 2'-O-methyl oligonucleotides in binding and inhibiting microRNA action (Fabani & Gait, 2009). In their experiments, PNAs were delivered by electroporation. Inhibition of miR-122 was evaluated by Northern blot and by the up-regulation effect upon both chemical and enzymatic degradation.

Interestingly, these authors showed that microRNA inhibition can be achieved without the need for transfection or electroporation, by conjugating the PNA to the cell-penetrating peptide R6-Penetratin, or merely by linkage to four Lys residues, highlighting the potential of PNAs for future therapeutic applications as well as for studying microRNA function. Both LNA/OMe and PNA oligomers were found to be much more effective than 2’-O-methyl RNA oligonucleotides usually used as anti-miR agents. The target miR disappeared from the Northen-blot analysis of the PNA-treated sample, suggesting a still unknown mechanism of degradation or segregation induced by PNA.

In a parallel work, Oh et al. described the effectiveness of miR targeting by PNA-peptide conjugates, using a series of cell penetrating peptides (CPP) as carriers, including R6 pen, Tat, a four Lys sequence, and transportan ( Oh, et al., 2009). The best conditions were obtained with cationic peptides, and in particular with the Tat-modified peptide RRRQRRKKRR. In this study, cells were transfected with a plasmid containing a luciferase gene carrying a target site for each miR tested. Inhibition of the miR activity was monitored by expression of the luciferase gene. Inhibition of miR-16, which regulates Bcl-2 expression, and of miR-21 activity could be monitored in this way. PNAs were found to be more effective than LNAs and 2’-OMe oligonucleotides (Figure 3 A). Furthermore, PNAs showed no cytotoxicity at the concentration used, unlike LNAs which showed a reduction in cell viability (Figure 3 B). Furthermore PNAs were found to be more resistant to degradation than LNAs, even if stored at room temperature, suggesting better performances of the former class as candidate drugs.

More recently, a PNA targeted against miR-155 has been used in cellular systems and in mice (Fabani et al., 2010). In this study, the induction of miR-155 by bacterial lipopolysaccharide (LPS) was reduced by using a PNA matching the miR target and linked to four lysine residues. Mice challenged with sub-lethal dose of LPS were treated with 50 mg PNA/kg/day for 2 days and 24 h after the last injection (At which time the miR-155 expression is maximal) they were sacrified and their spleen tissue was analysed. Complete suppression of miR-155 induction was observed. Genome-wide analysis of gene expression revealed a profile of normal mice treated with LPS and then with anti-miR PNA similar to transgenic miR-155-deficient animals receiving control PBS buffer.

This study revealed important clues on the miR-155 regulation of B-cells and suggested a possible use of anti-miR PNA in the treatment of diffuse large B-cell lymphoma (DLBCL).

In a recent study we evaluated the activity of a PNA targeting microRNA-210, which is firmly associated to hypoxia and is modulated during erythroid differentiation, in leukemic K562 cells (Fabbri et al., 2010). The major conclusions of our study were that a PNA against miR-210 conjugated with a polyarginine peptide (R-pep-PNA-a210): (a) is efficiently internalized within the target cells; (b) strongly inhibits miR-210 activity; (c) deeply alters the expression of raptor and γ-globin genes. Unlike commercially available antagomiRs, which need continuous administrations, a single administration of R-pep-PNA-a210 was sufficient to obtain the biological effects.

Figure 3.

A, B: Comparison of the PNA-based anti-miR activity and cellular toxicity with other oligonucleotide mimics as reported by Oh and coworkers (data from Oh et al., 2009). A) Effect of anti-miR on HeLa cells transfected with 200 nM of PNA, LNA-modified oligonucleotide, and a 2′-OMe-modified oligonucleotide (2′-OMe) specific for miR-24; a luciferase assay was performed to evaluate the effect anti-miR oligonucleotide mimics. B) Cell viability of HeLa cells after incubation with 200nm of PNA, LNA and 2’OMe oligonucleotides. (C-E) Cellular delivery and anti-miR210 activity of fluoresceinated R8-PNA. C. FACS analysis showing the uptake of fluoresceinated R8 peptide (R-pep), anti-miR-210 PNA (PNA-a210), and R8-PNA (R-pep-PNA-a210) after 48 hours incubation of K562 cells at a 2 M concentration. D. Intracellular distribution of K562 cells cultured for 48 hours with 2 M of Fluoresceinated Rpep-PNA-a210 and then analyzed using a fluorescence microscope. The picture is the merged analysis of the fluorescence and of the staining of the same cell population with Hoechst 33258 (selectively staining nuclei). E. Effects of the treatment with Rpep, PNA-a210, Rpep-PNA-a210 on the miR-210 content in K562 cells.

Interestingly, cellular uptake was found to be crucial in order to obtain biological activity, since the PNA lacking of the polyarginine tail (PNA-a210), despite being able to hybridize to target nucleotide sequences, displayed very low activity on cells (Figure 3 C-E).


5. Modified PNAs can improve miR targeting

The major limit in the use of PNAs for the alteration of gene expression is the low uptake by eukaryotic cells (Rasmussen et al., 2006). In order to remove this drawback, several approaches have been considered, including the delivery of PNA analogues with liposomes and microspheres (Nastruzzi et al., 2000, Cortesi et al., 2004, Borgatti, 2002). One of the possible strategy is to link PNAs to polylysine (K) or a polyarginine (R) tails, based on the observation that this cell-membrane penetrating oligopeptides are able to facilitate uptake of conjugated molecules (Abes et al., 2008).

Since their discovery, many modifications of the original PNA backbones have been proposed in order to improve performances in term of affinity and specificity.

Modification of the PNA backbone with positively charged groups (figure 4) has also been demonstrated to enhance cellular uptake and consequently PNA efficiency (Corradini et al., 2007, Zhou et al., 2003, 2006).

Figure 4.

Structure of backbone modified PNA.

Although the steric requirements for binding RNA have not been extensively studied so far, the availability of different chemical strategies to design and synthesize PNA analogues is the basis for the development of new peptide nucleic acids (PNAs) specifically aimed at targeting RNA, to be used for miR targeting.

In the last few years several research groups have been involved in the synthesis and in the studies of the binding properties of PNAs with a chiral constrained backbone obtained by insertion of stereogenic centers either at the C2 (alpha) or C5 (gamma) position of the monomer.

The insertion of one chiral monomeric unit in a PNA strand has resulted in increased DNA binding affinity, when the side chain was positively charged (e.g. lysine or arginine). The PNA:DNA duplex stability was found to be dependent on stereochemistry: PNAs carrying a monomer with a stereocenter derived from a D-amino acid at the C2 position bound complementary antiparallel DNA strands with higher affinity than the corresponding PNA carrying a monomer with a stereocenter derived from an L-amino acid at the same position. Therefore, the affinity of chiral PNAs for complementary DNA emerged to be a contribution of different factors: electrostatic interactions, steric hindrance and, most interestingly, enantioselectivity with a preference for the D-configuration at the 2 position of the monomer. A PNA:DNA duplex, in which three adjacent chiral monomers based on 2D-lysine ("chiral box") were present in the middle of the PNA strand, was characterized by X-ray diffraction, and the results showed that the D-lysine-based chiral PNA-DNA heteroduplex adopts the so-called P-helix conformation, with helical parameters significantly different from those of the canonical DNA helical forms (Menchise et al., 2003). The P-helix is characterized by a small twist angle, a large x-displacement and a wide, deep major groove. The 2D-lysine "chiral box" PNA showed also an increased sequence selectivity, both in terms of direction control and of recognition of a single base mismatch (Sforza et al., 2000). Therefore, this type of structures was found ideal for targeting point mutations in genes of diagnostic interest (Corradini et al., 2004, Tedeschi et al., 2005a,b). Recently chiral PNAs with L- or D-stereocenters either at the 2- or the 5-positions of the monomer or with both stereocenters simultaneously present have also been synthesized and studied (Sforza et al., 2007, Manicardi et al., 2010).76 The strongest directing factor was found to be the L-stereogenic center at position 5 derived from L-lysine. This preference (L-configuration at position 5) and the former (D-configuration at position 2) are related to the ability to form a preferred right-handed helicity of PNA and therefore a preferential preorganization for binding right-handed DNA.

More recently, three consecutive different chiral monomers, respectively modified with 2D-Arg, with 5L,2D-Arg and with 5L-Arg, were used by our group in order to build an "extended chiral box" PNA. Such PNA, analogously to the above mentioned "chiral box" PNA, showed very good mismatch discrimination towards DNA, was even more specific in RNA recognition, showing that PNA modifications can also be used in order to tailor PNA recognition towards RNA (Calabretta et al., 2011).

Recently, Ly and co-workers reported the synthesis and uptake properties of γGPNA, in which the PNA backbone had a homo-arginine side chain at the 5-position (or γ position) (Sahu et al., 2009), showing an excellent cellular uptake.

Substitution at both C2 and C5 carbons of the PNA backbone with amino acid side chains leads to ambivalent structures having properties of DNA or RNA mimic on one side and peptide mimics on the other side, thus allowing recognition by specific receptors, as shown very recently by a short PNA mimicking the function of a nuclear localization peptide (NLS) (Sforza et al., 2010). Thus, and to obtain PNAs with both peptide properties and RNA binding ability. This strategy can be used to further improve the efficiency of PNAs for miR targeting. In fact, the use of peptides as carriers represents a “Achille’s heel” of the potential PNA-based drug candidates, since the peptide part might be subjected to enzymatic degradation, whereas the incorporation of the peptide signal into the PNA backbone does not lead to enzymatic degradation, even in the presence of highly active proteases.

PNAs bearing modified nucleobases able to induce additional interactions providing high improvement in RNA and DNA binding affinities have also been described (Wojciechowski et al., 2009). Combination of modified nucleobases and backbone modification with C2 or C5 modified residues was found to be the best approach in order to achieve strand invasion into mixed DNA sequences (Ishizuka et al., 2008, 2009, Chenna et al., 2008), a strategy which could also be very fruitful in challenging double-stranded miRs.


6. Conclusions and perspectives

PNAs are very promising tools for the inhibition of miR activities, and this effect can be very important for obtaining gene modulation in a relatively simple way, with very important applications in gene therapy and in drug development.

The issue of the correct delivery of PNAs to their targets is still open, although efficient strategies have already been described, including conjugation with carrier peptides and backbone modification.

The very high affinity of PNAs for RNA and the very strong chemical and enzymatic stability of these compounds (especially the backbone-modified version) make them ideal candidates as miR inhibitors with long-lasting effect.

The first data available already indicate that this technology is likely to succeed, despite the limited number of targets studied so far. Apart from model systems, PNAs have the potentiality to perform like (and eventually outperform) other anti-miR agents such as 2’-OMe oligonucleotides and LNAs.

Furthermore, the possibility to introduce functional groups along the chain of the PNA strand by chemical synthesis allows to envisage strategies in which the PNA can be endowed of catalytic sites, thus leading to molecules not only capable of binding, but also of cleaving, leading to miR specific nuclease models.



This work was supported by a grant by MIUR (Italian Ministry of University and Research). RG is granted by Fondazione CARIPARO and Telethon GGP10124.


  1. 1. AbesR.ArzumanovA.MoultonH.AbesS.IvanovaG.GaitM. J.IversenP.LebleuB.2008Arginine-rich cell penetrating peptides: design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides.Journal of Peptide Science,144455460.1075-2617
  2. 2. Alvarez-GarciaI.MiskaE. A.2005MicroRNA functions in animal development and human disease.Development,1322146534662..0950-1991
  3. 3. BonhamM. A.BrownS.BoydA. L.BrownP. H.BruckensteinD. A.HanveyJ. C.ThomsonS. A.PipeA.HassmanF.BisiJ. E.FroehlerB. C.MatteucciM. D.WagnerR. W.NobleS. A.BabissL.1995An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers.Nucleic Acids Research,23711971203.0305-1048
  4. 4. BorgattiM.BredaL.CortesiR.NastruzziC.RomanelliA.SavianoM.BianchiN.MischiatiC.PedoneC.GambariR.2002Cationic liposomes as delivery systems for double-stranded PNA-DNA chimeras exhibiting decoy activity against NF-kappaB transcription factors.Biochemical Pharmacology,644609616.0006-2952
  5. 5. BrownB. D.NaldiniL.2009Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications.Nature Reviews Genetics108578585. ISSN. 1471-0056.
  6. 6. CalabrettaA.TedeschiT.CorradiniR.MarchelliR.SforzaS.2011DNA and RNA binding properties of an arginine-based “Extended Chiral Box” Peptide Nucleic Acid.Tetrahedron Letters,522300304.0040-4039
  7. 7. CalinG. A.CroceC. M.2006MicroRNA signatures in human cancers.Nature Reviews Cancer611857866.0147-4175X.
  8. 8. CeppiM.PereiraP. M.Dunand-SauthierI.BarrasE.ReithW.SantosM. A.PierreP.2009MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells.Proceedings of the National Academy of Sciences U.S.A.106827352740.0027-8424
  9. 9. ChoW. C. S.2007OncomiRs: the discovery and progress of microRNAs in cancers.Molecular Cancer,6Art.601476-4598
  10. 10. CorradiniR.FeriottoG.SforzaS.MarchelliR.GambariR.2004Enhanced recognition of cystic fibrosis W1282X DNA point mutation by chiral peptide nucleic acid probes by a surface plasmon resonance biosensor.Journal of Molecular Recognition,1717684..0952-3499
  11. 11. CorradiniR.SforzaS.TedeschiT.TotsinganF.MarchelliR.2007Peptide Nucleic Acids with a Structurally Biased Backbone: Effects of Conformational Constraints and Stereochemistry.Current Topics in Medicinal Chemistry,77681694.1568-0266
  12. 12. CorstenM. F.MirandaR.KasmiehR.KrichevskyA. M.WeisslederR.ShahK.2007MicroRNA-21 Knockdown Disrupts Glioma Growth In vivo and Displays Synergistic Cytotoxicity with Neural Precursor Cell-Delivered S-TRAIL in Human Gliomas.Cancer Research671989949000.0008-5472
  13. 13. CortesiR.MischiatiC.BorgattiM.BredaL.RomanelliA.SavianoM.PedoneC.GambariR.NastruzziC.2004Formulations for natural and peptide nucleic acids based on cationic polymeric submicron particles.AAPS Pharmsci,611021.1522-1059
  14. 14. CostineanS.ZanesiN.PekarskyY.TiliE.VoliniaS.HeeremaN.CroceC. M.2006Pre-B cell proliferation and lymphoblastic leukemia/ high-grade lymphoma in E(mu)-miR155transgenic mice. Proc Natl Acad Sci USA1031870247029..0027-8424
  15. 15. CzechM. P.2006MicroRNAs as Therapeutic Targets.New England Journal of Medicine,3541111941195. ISSN.
  16. 16. DemidovV. V.PotamanV. N.Frank-KamenetskiiM. D.EgholmM.BuchardO.SonnichsenS. H.NielsenP. E.1994Stability of peptide nucleic acids in human serum and cellular extracts.Biochemical Pharmacology,48613101313.0006-2952
  17. 17. Dragulescu-AndrasiA.ZhouP.HeG.LyD. H.2005Cell-permeable GPNA with appropriate backbone stereochemistry and spacing binds sequence-specifically to RNAChemical Communications,33244246.1359-7345
  18. 18. EdmondsM. D.HurstD. R.WelchD. R.2009Linking metastasis suppression with metastamiR regulation.Cell Cycle.81726732675.1538-4101
  19. 19. ElménJ.LindowM.SilahtarogluA.BakM.ChristensenM.Lind-Thomsen2008; Bak, M.; Christensen, M. & Lind-Thomsen, A. (2008 a) Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver.Nucleic Acids Research36411531162.0305-1048
  20. 20. ElménJ.LindowM.SchützS.LawrenceM.PetriA.ObadS.LindholmM.HedtjärnM.HansenH. F.BergerU.GullansS.KearneyP.SarnowP.StraarupE. M.Kauppinen2008; Lawrence, M.; Petri, A.; Obad S.; Lindholm M.; Hedtjärn, M.; Hansen, H.F.; Berger, U.; Gullans, S.; Kearney, P.; Sarnow, P.; Straarup, E.M. & Kauppinen, S. (2008 b) LNA-mediated microRNA silencing in non-human primates.Nature,4527189896900.0028-0836
  21. 21. FabaniM. M.GaitM. J.2008miR-122 targeting with LNA/2’-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates.RNA.142336346.1355-8382
  22. 22. FabaniM. M.Abreu-GoodgerC.WilliamsD.LyonsP. A.TorresA. G.SmithK. G. C.EnrightA. J.GaitM. J.VigoritoE.2010Efficient inhibition of miR-155 function in vivo by peptide nucleic acids.Nucleic Acids Research,381344664475.0305-1048
  23. 23. FabbriE.BianchiN.BrognaraE.FinottiA.BreveglieriG.BorgattiM.ManicardiA.CorradiniR.MarchelliR.GambariR.2010Inhibition of micro RNA 210 biological activity with an anti-miR-210 peptide nucleic acid.International Journal of Molecular Medicine,26Suppl. 1.,S61S61.1107-3756
  24. 24. FilipowiczW.JaskiewiczL.KolbF. A.PillaiR. S.2005Post-transcriptional gene silencing by siRNAs and miRNAs.Current Opinions in Structural Biology,153331341.0095-9440X.
  25. 25. GambariR.2004Biological activity and delivery of peptide nucleic acids (PNA)-DNA chimeras for transcription factor decoy (TFD) pharmacotherapy.Current Medicinal Chemistry,111012531263.0929-8673
  26. 26. GarzonR.CroceC. M.2008MicroRNAs in normal and malignant hematopoiesis.Current Opinions in Hematology,154352358.1065-6251
  27. 27. HayashitaY.OsadaH.TatematsuY.YamadaH.YanagisawaK.TomidaS.YatabeY.KawaharaK.SekidoY.TakahashiT.2005A polycistronic microRNA cluster,miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Research652196289632.1078-0432
  28. 28. HeL.HannonG. J.2004MicroRNAs: small RNAs with a big role in gene regulation.Nature Reviews Genetics7522531.1471-0056
  29. 29. HuangC.LiM.ChenC.YaoQ.2008Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications.Expert Opinions in Therapeutic Targets,125637645.1472-8222
  30. 30. HurstD. R.EdmondsM. D.WelchD. R.2009Metastamir: the field of metastasis-regulatory microRNA is spreading.Cancer Research.691974957498.1078-0432
  31. 31. IorioM. V.FerracinM.LiuC. G.VeroneseA.SpizzoR.SabbioniS.MagriE.PedrialiM.FabbriM.CampiglioM.MenardS.PalazzoJ. P.RosenbergA.MusianiP.VoliniaS.NenciI.CalinG. A.QuerzoliP.NegriniM.CroceC. M.2005MicroRNA gene expression deregulation in human breast cancer.Cancer Research651670657070.1078-0432
  32. 32. IshizukaT.TedeschiT.CorradiniR.KomiyamaM.SforzaS.MarchelliR.2009SSB-Assisted Duplex Invasion of Preorganized PNA into Double-Stranded DNA.ChemBioChem,101626072612.1439-4227
  33. 33. IshizukaT.YoshidaJ.YamamotoY.SumaokaJ.TedeschiT.CorradiniR.SforzaS.KomiyamaM.2008Chiral introduction of positive charges to PNA for double-duplex invasion to versatile sequences.Nucleic Acid Research.,36514641471.0305-1048
  34. 34. JoplingC. L.YiM.LancasterA. M.LemonS. M.SarnowP.2005Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA.Science,309574015771581.0036-8075
  35. 35. KongW.HeL.CoppolaM.GuoJ.EspositoN. N.CoppolaD.ChengJ. Q.2010MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer.Journal of Biological Chemistry285231786917879.0021-9258
  36. 36. KotaS. K.BalasubramanianS.2010Cancer therapy via modulation of micro RNA levels: a promising future.Drug Discovery Today.151718,733740.1359-6446
  37. 37. KozomaraA.Griffiths-JonesS.2010miRBase: integrating microRNA annotation and deep-sequencing data.Nucleic Acids Research,39DatabaseD152-D157.0305-1048
  38. 38. KrolJ.LoedigeI.FilipowiczW.2010The widespread regulation of microRNA biogenesis, function and decay.Nature Reviews Genetics,119597610.1471-0056
  39. 39. KrutzfeldtJ.KuwajimaS.BraichR.RajeevK. G.PenaJ.TuschlT.ManoharanM.StoffelM.2007Specificity, duplex degradation and subcellular localization of antagomirs.Nucleic Acids Research,35928852892.0305-1048
  40. 40. KrützfeldtJ.RajewskyN.BraichR.RajeevK. G.TuschlT.ManoharanM.StoffelM.2005Silencing of microRNAs in vivo with ‘antagomirs’.Nature,4387068685689.0028-0836
  41. 41. LanfordR. E.Hildebrandt-EriksenE. S.PetriA.PerssonR.LindowM.MunkM. E.KauppinenS.ØrumH.2010Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection.Science,3275962198201.0036-8075
  42. 42. LarsenH. J. .NielsenP. E.1996Transcription-mediated binding of peptide nucleic acid (PNA) to double-stranded DNA: sequence-specific suicide transcription.Nucleic Acids Research,243458463.0305-1048
  43. 43. Le SageC.NagelR.EganD. A.SchrierM.MesmanE.MangiolaA.AnileC.MairaG.MercatelliN.CiafrèS. A.FaraceM. G.AgamiR.2007Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation.EMBO Journal261536993708.0261-4189
  44. 44. LiS. D.HuangL.2008Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.Current Opinion in Investigational Drugs,91213171323.1472-4472
  45. 45. LiuX.SempereL. F.OuyangH.MemoliV. A.AndrewA. S.LuoY.DemidenkoE.KorcM.ShiW.PreisM.DragnevK. H.LiH.DirenzoJ.BakM.FreemantleS. J.KauppinenS.DmitrovskyE.2010MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors.Journal of Clinical Investigations120412981309.0021-9738
  46. 46. López-FragaM.WrightN.JiménezA.2008RNA interference-based therapeutics: new strategies to fight infectious disease.Infection Disorders-Drug Targets,84262273.1871-5265
  47. 47. LoweryA. J.MillerN.Mc NeillR. E.KerinM. J.2008MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management.Clinical Cancer Research,142360365..1078-0432
  48. 48. LundinK. E.GoodL.StrömbergR.GräslundA.SmithC. I.2006Biological activity and biotechnological aspects of peptide nucleic acid.Advances in Genetics56151.0065-2660
  49. 49. ManicardiA.CalabrettaA.BencivenniM.TedeschiT.SforzaS.CorradiniR.MarchelliR.2010Affinity and Selectivity of C2- and C5-Substituted ‘‘Chiral-Box’’ PNA in Solution and on Microarrays.Chirality22No.IE,E161E172.0899-0042
  50. 50. MasakiS.OhtsukaR.AbeY.MutaK.UmemuraT.2007Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis.Biochemical and Biophysical Research Communication3643509514.0000-6291X.
  51. 51. MascellaniN.TagliaviniL.GamberoniG.RossiS.MarchesiniJ.TaccioliC.Di LevaG.NegriniM.CroceC.VoliniaS.2008Using miRNA expression data for the study of human cancer.Minerva Biotecnologica,2012330.1120-4826
  52. 52. MenchiseV.De SimoneG.TedeschiT.CorradiniR.SforzaS.MarchelliR.CapassoD.SavianoM.PedoneC.2003Insights into peptide nucleic acid (PNA) structural features: The crystal structure of a D-lysine-based chiral PNA-DNA duplex.Proceedings of the National Academy of Sciences U.S.A.,100211202112026.0027-8424
  53. 53. NastruzziC.CortesiR.EspositoE.GambariR.BorgattiM.BianchiN.FeriottoG.MischiatiC.2000Liposomes as carriers for DNA-PNA hybrids.Journal of Controlled Release,682237249.0168-3659
  54. 54. NielsenP. E. .Ed.2004Peptide Nucleic Acids: Protocols and Applications, Second Edition, Horizon Bioscience,0-95452-324-5UK).
  55. 55. NielsenP. E.2006RNA targeting using peptide nucleic acid.Handbook of Experimental Pharmacology173395403.0171-2004
  56. 56. NielsenP. E.EgholmM.1999An introduction to peptide nucleic acid.Curent Issues in Molecular Biology1289104.1467-3037
  57. 57. NielsenP. E.2005Gene targeting using peptide nucleic acid.Methods in Molecular Biology.288343358.1064-3745
  58. 58. NielsenP. E.EgholmM.BergR. H.BuchardtO.1991Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide.Science254503714971500.0036-8075
  59. 59. OhS. Y.JuY. S.ParkH.2009A Highly effective and long-lasting inhibition of miRNA with PNA-based antisense oligonucleotides.Molecules and Cells284341345.1016-8478
  60. 60. OrlacchioA.BernardiG.OrlacchioA.MartinoS.2007RNA interference as a tool for Alzheimer’s disease therapy.Mini Reviews in Medicinal Chemistry,71111661176.1389-5575
  61. 61. PapagiannakopoulosT.KosikK. S.2008aa) MicroRNAs: regulators of oncogenesis and stemness.BMC Medicine,6151741-7015
  62. 62. PapagiannakopoulosT.ShapiroA.KosikK. S.2008bb) MicroRNA-21 Targets a Network of Key Tumor-Suppressive Pathways in Glioblastoma Cells.Cancer Research681981648172.0008-5472
  63. 63. PedersenI. M.OteroD.KaoE.MileticA. V.HotherC.RalfkiaerE.RickertR. C.GronbaekK.DavidM.2009Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas.EMBO Molecular Medicine.15288295.ISSN. 1757-4676.
  64. 64. RasmussenF. W.BendifallahN.ZacharV.ShiraishiT.FinkT.EbbesenP.NielsenP. E.KoppelhusU.2006Evaluation of transfection protocols for unmodified and modified peptide nucleic acid (PNA) oligomers. Oligonucleotides1614357.1545-4576
  65. 65. SahuN. K.ShilakariG.NayakA.KohliD. V.2007Antisense technology: a selective tool for gene expression regulation and gene targeting.Current Pharmaceutical Biotechnology,85291304.1389-2010
  66. 66. SforzaS.CorradiniR.GhirardiS.DossenaA.MarchelliR.2000DNA Binding of a D-Lysine-Based Chiral PNA: Direction Control and Mismatch Recognition.European Journal of Organic Chemistry.1629052913.0143-4193X.
  67. 67. SforzaS.TedeschiT.CalabrettaA.CorradiniR.CamerinC.TonelliR.PessionA.MarchelliR.2010A Peptide Nucleic Acid Embedding a Pseudopeptide Nuclear Localization Sequence in the Backbone Behaves as a Peptide Mimic.European Journal of Organic Chemistry1324412444.0143-4193X
  68. 68. SforzaS.TedeschiT.CalabrettaA.CorradiniR.CamerinC.TonelliR.PessionA.MarchelliR.(2012010)Apeptide nucleic acid embedding a pseudo peptide nuclear localization sequence in the backbone bahave as a peptide mimic.European Journal of Organic Chemistry,1324412444.0143-4193X.
  69. 69. SforzaS.TedeschiT.CorradiniR.MarchelliR.2007Induction of Helical Handedness and DNA Binding Properties of Peptide Nucleic Acids (PNAs) with Two Stereogenic Centres.European Journal of Organic Chemistry,3558795885.0143-4193X
  70. 70. ShrivastavaN.SrivastavaA.2008RNA interference: an emerging generation of biologicals.Biotechnology Journal,33339353. ISSN. 1860-7314.
  71. 71. SiM. L.ZhuS.WuH.LuZ.WuF.MoY. Y.2007miR-21-mediated tumor growth. Oncogene261927992803.0950-9232
  72. 72. SontheimerE. J.CarthewR. W.2005Silence from within: endogenous siRNAs and miRNAs.Cell,1221912.0092-8674
  73. 73. StenvangJ.KauppinenS.2008MicroRNAs as targets for antisense-based therapeutics.Expert Opinions in Biological Therapy,815981.1471-2598
  74. 74. SubramanianS.SteerC. J.2010MicroRNAs as gatekeepers of apoptosis.Journal of Cellular Physiology,2232289298.0021-9541
  75. 75. TedeschiT.ChiariM.GalavernaG.SforzaS.CretichM.CorradiniR.Marchelli2005& Marchelli, R. (2005 b) Detection of the R553X DNA single point mutation related to cystic fibrosis by a “chiral box” D-lysine-peptide nucleic acid probe by capillary Electrophoresis.Electrophoresis262243104316.0173-0835
  76. 76. TedeschiT.SforzaS.CorradiniR.Marchelli2005& Marchelli, R. (2005 c) Synthesis of new chiral PNAs bearing a dipeptide-mimic monomer with two lysine-derived stereogenic centres.Tetrahedron Letters,464883958399.0040-4039
  77. 77. TedeschiT.SforzaS.DossenaA.CorradiniR.Marchelli2005& Marchelli R. (2005 a) Lysine-based peptide nucleic acids (PNAs) with strong chiral constraint: control of helix handedness and DNA binding by chirality.Chirality17S196-S204.
  78. 78. TribouletR.MariB.LinY. L.Chable-BessiaC.BennasserY.LebrigandK.CardinaudB.MaurinT.BarbryP.BaillatV.ReynesJ.CorbeauP.JeangK. T.BenkiraneM.2007Suppression of microRNA-silencing pathway by HIV-1 during virus replication.Science.315581815791582.0036-8075
  79. 79. VisoneR.RussoL.PallanteP.De MartinoI.FerraroA.LeoneV.BorboneE.PetroccaF.AlderH.CroceC. M.FuscoA.2007MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle.Endocrine-Related Cancer.143791798.1351-0088
  80. 80. WangY. M.BlellochR.2009Cell cycle regulation by MicroRNAs in embryonic stem cells.Cancer Research691040934096.0008-5472
  81. 81. WilliamsA. E.PerryM. M.MoschosS. A.Larner-SvenssonH. M.LindsayM. A.2008Role of miRNA-146a in the regulation of the innate immune response and cancer.Biochemical Society Transactions,36No. (Pt 6),12111215. ISSN. 0300-5127.
  82. 82. WojciechowskiF.HudsonR. H. E.2007Nucleobase modifications in peptide nucleic acidsCurrent Topics in Medicinal Chemistry,77667679.1568-0266
  83. 83. WojciechowskiF.HudsonR. H. E.2009Peptide Nucleic Acid Containing a Meta-Substituted Phenylpyrrolocytosine Exhibits a Fluorescence Response and Increased Binding Affinity toward RNA.Organic Letters112148784881.1523-7060
  84. 84. WoodsK.ThomsonJ. M.HammondS. M.2007Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors.Journal of Bioogical Chemistry282421302134.0021-9258
  85. 85. YinH.LuQ.WoodM.2008Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice.Molecular Therapy1613845.1525-0016
  86. 86. ZhangB.PanX.CobbG. P.AndersonT. A.2007microRNAs as oncogenes and tumor suppressors.Developmental Biology3021112.0012-1606
  87. 87. ZhangC. Z.ZhangJ. X.ZhangA. L.ShiZ. D.HanL.JiaZ. F.YangW. D.WangG. X.JiangT.YouY. P.PuP. Y.ChengJ. Q.KangC. S.2010MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma.Molecular Cancer.92291476-4598
  88. 88. ZhouP.Dragulescu-AndrasiA.BhattacharyaB.O’KeefeH.VattaP.Hyldig-NielsenJ. J.LyD. H.2006Synthesis of cell-permeable peptide nucleic acids and characterization of their hybridization and uptake properties.Bioorganic and Medicinal Chemistry Letters,161849314935.0096-0894X.
  89. 89. ZhouP.WangM. M.DuL.FisherG. W.WaggonerA.LyD. H.2003Novel Binding and efficient Cellular Uptake of Guanidine-Based Peptide Nucleic Acids (GPNA).Journal of the American Chemical Society,1252368786879.0002-7863
  90. 90. ZhuS.SiM. L.WuH.MoY. Y.2007MicroRNA-21Targets the tumor suppressor gene Tropomyosin 1 (TPM1). Journal of Biological Chemistry282191432814336.0021-9258

Written By

Rosangela Marchelli, Roberto Corradini, Alex Manicardi, Stefano Sforza, Tullia Tedeschi, Enrica Fabbri, Monica Borgatti, Nicoletta Bianchi and Roberto Gambari

Submitted: November 11th, 2010 Published: August 23rd, 2011